1. How can diabetologists recognise patients with lipodystrophies and Myalepta? (0:12)
2. What will it mean for patients with lipodystrophy that Myalepta is now available in Europe? (1:30)
3. What is important for doctors when seeing patients with lipodystrophy? (2:52)
Speaker's disclosures: Speaker’s fees from Aegerion, Consultant to Rhythm Pharmaceuticals.
This video is intended for health care professionals.
Information for patients and carers can be found here
Product information on metreleptin is available here
Adverse reactions should be reported to Aegerion by email: Medinfo.email@example.com or by telephoning the free phone number: 00800 234 37466
Filmed at the European Association for the Study of Diabetes (EASD) annual meeting, Berlin, Germany, 2018